drugset
drugset / Trial / NCT03743766

Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

NCT03743766 ↗

Phase 2 Completed 42 enrolled John Kirkwood Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.

Timeline

Start
2019-03-29
Primary completion
2024-07-03
Completion
2024-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Subject Relatlimab Monoclonal antibody 160 mg Intravenous

Indications

melanoma